` CVRX (CVRx Inc) vs S&P 500 Comparison - Alpha Spread

CVRX
vs
S&P 500

Over the past 12 months, CVRX has underperformed S&P 500, delivering a return of -23% compared to the S&P 500's 12% growth.

Stocks Performance
CVRX vs S&P 500

Loading

Performance Gap
CVRX vs S&P 500

Loading
CVRX
S&P 500
Difference

Performance By Year
CVRX vs S&P 500

Loading
CVRX
S&P 500
Add Stock

Competitors Performance
CVRx Inc vs Peers

CVRx Inc
Glance View

Market Cap
165.2m USD
Industry
Health Care

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.

CVRX Intrinsic Value
10.15 USD
Undervaluation 38%
Intrinsic Value
Price
C
Back to Top